Efficacy of naltrexone in the treatment of chronic refractory itching in burn patients: Preliminary report of an open trial

27Citations
Citations of this article
37Readers
Mendeley users who have this article in their library.

Abstract

Pruritis (itching) constitutes a source of severe distress for burn patients. The authors administered naltrexone to burn patients suffering from itching that was refractory to treatment with antihistamine and anticonvulsant medications to examine the efficacy of this medication as a treatment for pruritis in burn patients. Nineteen burn patients admitted to the Hailym Burn Center at Hangang Sacred Heart Hospital in Seoul, Korea, with burns over 40.32% (±18.3) of their total body surface were recruited for this study. The mean number of postburn days before naltrexone treatment was 157.3 days (±114.7). The authors observed a significant decrease in itching sensations after 2 weeks of treatment with naltrexone (z = -3.32, P = .001). Scratching activity was also decreased in 44.5% (±20.5) of subjects. The authors propose that naltrexone constitutes a potential antipruritk medication for burn patients suffering from treatment-refractory itching. Copyright © 2009 by the American Burn Association.

Cite

CITATION STYLE

APA

Jung, S. I., Seo, C. H., Jang, K., Ham, B. J., Choi, I. G., Kim, J. H., & Lee, B. C. (2009). Efficacy of naltrexone in the treatment of chronic refractory itching in burn patients: Preliminary report of an open trial. Journal of Burn Care and Research, 30(2), 257–260. https://doi.org/10.1097/BCR.0b013e318198a282

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free